Pirfenidone superior to nintedanib for preventing acute exacerbation of IPF
Pirfenidone appears to confer greater reduction in the risk of acute exacerbation among patients with idiopathic pulmonary fibrosis (IPF) as compared with nintedanib, as shown in a study.
Pirfenidone superior to nintedanib for preventing acute exacerbation of IPF
05 Aug 2021
